Drug
Lorvotuzumab mertansine clinical trials
Also written BB-10901 and IMGN901.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2015 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 2
ImmunoGen, Inc. (5) · Children's Oncology Group (1) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses lorvotuzumab mertansine is read from its arms, and is right about nine times in ten.
Testing it · 7
- Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial SarcomaCompletedPhase 2Children's Oncology GroupNCT02452554Written as Lorvotuzumab Mertansine
- An Open-label Phase II Study of Lorvotuzumab MertansineCompletedPhase 2M.D. Anderson Cancer CenterNCT02420873Written as Lorvotuzumab Mertansine (IMGN901)
- A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2ImmunoGen, Inc.NCT01237678Written as IMGN901
- BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedPhase 1ImmunoGen, Inc.NCT00346385Written as BB-10901
- IMGN901 in Combination With Lenalidomide and DexamethasoneCompletedPhase 1ImmunoGen, Inc.NCT00991562Written as IMGN901
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedPhase 1ImmunoGen, Inc.NCT00346255Written as BB-10901
- Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung CancerCompletedPhase 1/2ImmunoGen, Inc.NCT00065429Written as BB-10901
Codes
What other systems call lorvotuzumab mertansine · ClinicalTrials.gg INT006254
- MeSH (NLM) C579429lorvotuzumab mertansineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0IVD6ASY0WLORVOTUZUMAB MERTANSINEConfirmed FDA, NLM
- NCI Thesaurus C38714Lorvotuzumab MertansineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579429 | lorvotuzumab mertansine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0IVD6ASY0W | LORVOTUZUMAB MERTANSINE | Confirmed FDA, NLM |
| NCI Thesaurus | C38714 | Lorvotuzumab Mertansine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.